Abstract. The ratio, clinical characteristics, and therapeutic efficacy of hGH treatment in patients with severe short stature (HtSDS below -4SD) with severe GHD (all peak GH values to provocation tests: below 2 mg/L) were studied. From March 1986 to January 1998, 23,110 patients with idiopathic GH deficiency (IGHD) were registered with the Foundation for Growth Science, Japan. These subjects were divided into 5 groups as follows: Group 1 (G1), all subjects; Group 2 (G2), at least one GH peak to provocative test ³5 mg/L; Group 3 (G3), 2 mg/L£GH peak<5 mg/L; Group 4 (G4), all GH peaks<2 mg/L and HtSDS>-4; Group 5 (G5), all GH peaks<2 mg/L and HtSDS£-4. The ratio of G5 was 139 patients (0.6%) out of 23,110 patients with IGHD. In G5, there were no significant differences in birth weight, birth length, gestational age and parental height between G2, G3 and G4. However, asphyxia at delivery was more frequent in G5 and G4 than G2 and G3. Chronological age (CA), bone age (BA) and BA/CA ratio at registration were significantly lower in G5 than G2, G3 and G4. Further, the IGF-I SD score in G5 was significantly lower than those in G2 and G3. After hGH treatment, the final height and final height SDS in G5 remained the lowest, while the DHtSDS value in G5 was the greatest among G2 to G5 groups. In conclusion, the ratio of severe short stature with severe GH deficiency (G5) is only 0.6% of all IGHD cases. Growth failure in G5 seems to occur after birth, and its etiology in G5 seems to be different from that of patients with other forms of IGHD. Early diagnosis and hGH treatment are needed to attain better final height.
RECENTLY, many growth disorders caused by genetic abnormalities, such as GH-1 gene, its transcription factors (Pit-1, PROP-1, HESX-1), GHRH-receptor gene, GH receptor gene and IGF-I receptor gene have been reported [1] [2] [3] . These cases, except for patients with gene mutations of GH receptor or IGF-I receptor, usually show severe short stature (height SD score below -4 to -4.5) together with severe GH deficiency (peak GH value below 4 mg/L in conventional provo-cation tests) [4] .
Short stature associated with GH deficiency is reported to be between 1 in 4,000 and 1 in 10,000 of the population in several studies [5] [6] [7] [8] . However, the exact incidence of severe short stature with severe GH deficiency (GHD) among total short stature patients (HtSDS below -2), and the proportion of GH-related gene abnormalities in severe short stature with severe GHD have yet to be clarified. In the present study, we examined the ratio of patients with severe short stature and severe GHD in total idiopathic GHD (IGHD), and studied the clinical characteristics and therapeutic efficacy of hGH in these patients.
Subjects and Methods
Patients with IGHD who were approved by the Foundation for Growth Science (FGS), Japan from March, 1986 to January, 1998, to receive hGH treatment, were studied. These patients were non-organic and received no gonadal suppression therapy.
IGHD was diagnosed according to the following criteria: (1) age matched height SDS (HtSDS) was below -2 or growth rate/year was below -1.5 SD over 2 years, and (2) poor GH responses (peak GH value to provocation test was below 10 mg/L) to two provocative stimuli; or the poor GH response to at least one stimulus and significantly low IGF-I value; or (3) low mean nocturnal GH value (below 3 mg/L) for 3 hr samplings at 20 min intervals together with low IGF-I and low urinary GH values despite normal GH responses to exogenous stimuli (so-called GH neurosecretory dysfunction). After registration with the Foundation for Growth Science (FGS), these patients were treated with recombinant human GH with the doses of 0.5IU = 0.17 mg/kg/week mainly 6 to 7 times a week.
These subjects were arbitrarily divided into 5 groups as follows: Group 1 (G1), all subjects; Group2 (G2), at least one GH peak to provocative test ³5 mg/L; Group 3 (G3), 2 mg/L£GH peak<5 mg/L, Group 4 (G4); all GH peaks<2 mg/L and HtSDS>-4 and; Group 5 (G5), all GH peaks<2 mg/L and HtSDS£-4. In this category, G1 is not simply the sum of G2, G3, G4 and G5, since one case which performed only one provocative test and whose peak GH value was below 5 mg/L, or one case whose one peak GH value was below 2 mg/L while the other value was more than 2 and below 5, were included in G1 but excluded from the other groups.
These five groups were analyzed based on the following parameters: (1) the number of each group at registration to FGS, (2) birth weight, (3) birth length, (4) gestational age, (5) incidence of asphyxia at delivery, (6) chronological age (CA) and (7) bone age (BA) at registration, (8) BA/CA ratio, (9) height at start of hGH treatment, (10) Height SDS (HtSDS) at start of hGH treatment, (11) SD score of serum IGF-I value (measured by RIA using extraction method) calculated from values of age-matched controls [9] at start of hGH treatment, (12) father's height, (13) mother's height, (14) final height (when growth rate fell below 2 cm/yr), (15) final height SDS, (16) DHtSDS (final HtSDSpretreatment HtSDS).
Data are expressed as mean ± S.E.M. and statistical analysis was conducted using Student's non-paired t-test or chi-square test for the comparison of the two parameters.
Results

1) Number of each group of idiopathic GH deficiency
As shown in Table 1 , total number of patients (G1) in this study was 23,110. Among them, the majority of patients (89.1%) were G2. So-called classical severe GHD (all GH peaks to provocation tests less than 5 mg/ L) was 10.5% (2428 cases) of the total, and severe short stature with severe GHD (G5) was only 0.6% (139 cases).
2) Birth weight, birth length, gestational age and asphyxia at delivery in the 5 groups
In all groups, birth weight (G1: boy, 2913.3 ± 4.0 g, n = 15,487; girl 2840.1 ± 5.7 g, n = 7,128; G5: boy, 2978.4 ± 61.6 g, n = 81; girl, 2939.3 ± 94.9 g, n = 54) (Table 2a) , birth length (G1: boy, 48.1 ± 0.04 cm, n = 4,431; girl, 47.6 ± 0.07 cm, n = 2,163; G5: boy, 46.5 ± 2.56 cm, n = 5; girl, 47.3 ± 0.87 cm, n=6) (Table 2b ) and gestational age [G1 (total), 39.1 ± 0.01 weeks, n = 22,110; G5 (total), 38.9 ± 0.24 weeks, n = 129] (Table 2c) were within normal ranges. The birth weight of patients in G5 was slightly greater than G2, G3 and G4 (P = NS). There were no significant differences in these parameters between G5 and G2, G3, G4; and no differences between each group. Asphyxia at delivery was seen in 12.3% of total cases, and the rate was significantly higher in G5 (21.8% vs G2, G3, P<0.01; vs G4, P = NS) and G4 (19.5% vs G2 and G3, P<0.01) ( Table 3 ).
3) Chronological age (CA), bone age (BA) and ratio of BA/CA in 5 groups at registration Although, the mean chronological age of G1 at registration was 9.5 ± 0.02 yr (n = 23,109), G5 was significantly younger (8.7 ± 0.4 yr, n = 139) than G2, G3 and G4 (P<0.005) (Table 4a ). Mean bone age in G5 (4.8 ± 0.33 yr, n = 120) was also significantly younger than G2, G3 and G4 [the totals of G2, G3 and G4 were 6.9 ± 0.02 yr, n = 19,955; 7.4 ± 0.09 yr, n = 1,711 and 7.4 ± 0.20 yr, n = 339, respectively] (P<0.001) (Table  4b) .
Further, the ratio of BA/CA in G5 (0.52 ± 0.02, n = 120) was significantly lower than G2, G3 and G4 (P<0.001). The value of G4 (0.69 ± 0.01, n = 339) was also significantly lower than G2 (0.72 ± 0.001, n = 19,954) (P<0.01) and G3 (0.71 ± 0.005, n = 1,711) (P<0.05) (Table 4c) .
Patients with severe GH deficiency (G4 + G5; all GH peaks to provocative stimuli were below 2 mg/L) showed a significantly lower BA/CA ratio compared to G2 and G3, while the ratios of the latter two groups were not significantly different.
4) Height, height SDS and serum IGF-I SD score in the 5 groups just before hGH treatment
As it was arbitrarily classified, pretreatment height (103.0 ± 2.0 cm, n = 139) and HtSDS (-4.98 ± 0.08, n = 139) in G5 were significantly lower than G2, G3 and G4 (P<0.001) (Table 5a , 5b).
HtSDS in G3 was significantly lower than that in G2 (P<0.01), and HtSDS in patients with severe GH deficiency (G4 + G5) were significantly lower than that in G2 and G3 (P<0.001).
Mean pretreatment serum IGF-I values (SDS) in G5
(-2.38 ± 0.48, n = 18) was significantly lower than in G2 and G3 (G2, -1.38 ± 0.01, n = 9,982; G3, -1.64 ± 0.06, n = 564) (P<0.001 and 0.05) ( Table 6 ). There were no significant differences between the values in G4 and G5. The IGF-I SD score in G3 and patients with severe GH deficiency (G4 + G5) were significantly lower than that in G2 (both P<0.01), but there was no difference in the values between the former two groups.
5) Parental height in the 5 groups
Parental height of each group was within the normal ranges and there were no differences among G2 to G5 groups (Table 7) .
6) Improvement of HtSDS, final height and final
HtSDS in the 5 groups after hGH treatment Improvement of HtSDS (DHtSDS) by hGH treatment was the greatest in G5 (+2.02 ± 0.51, n = 16) [vs G2 (+0.99 ± 0.02, n = 1,482), G3 (+0.97 ± 0.08, n = 250) and G4 (+0.93 ± 0.09, n = 80), P<0.025]. However, there were no significant differences among the other groups (G2 to G4) (Table 8a) . Although G5 had the best DHtSDS, the final height (boy, 154.8 ± 4.5 cm; girl, 141.6 ± 2.3 cm) and the final height SDS (total, -2.97 ± 0.51; boy, -2.80 ± 0.81, n = 10; girl, -3.22 ± 0.44, n = 7) of G5 were the lowest among the four (G2 to G5) groups (P<0.025) (Table 8b, 8c).
Discussion
The ratio of very severe short stature with severe GH deficiency (G5) was 139 (0.6%) out of 23,110 patients with IGHD. In G5, there were no significant differences in birth length and gestational age between G2, G3, and G4. However, birth weight in G5 was slightly greater than those of the other groups and asphyxia at delivery was more frequent in G5 and G4, than in G2 and G3.
These results indicate that patients with very severe GHD (G4 + G5) have greater risk of asphyxia at delivery compared to other groups despite normal intrauterine growth. Parental height in G5 was similar to G2 to G4, but their chronological age (CA), bone age (BA) and BA/ CA ratio at registration were significantly lower than these groups. As it was arbitrarily defined, pretreatment height and HtSDS in G5 were significantly lower than G2 to G4. IGF-I SD score in G5 was lower than G2 and G3, although there were no statistical differences between G5 and G4.
These results indicate that growth failure in G5 is not based mainly on familial origin, but is dependent upon their own GH deficiency. Such severe short stature might tend to make their parents to consult specialists earlier for growth disorders. It is reported that patients with severe GHD tend to have been diagnosed at a younger age [10, 11] .
Although it did not reach statistical significance, mean IGF-I SD score in G5 was lower than that of G4. In addition, mean BA/CA ratio in G5 was significantly lower than that of G4. Therefore, it seems that GH secretory capacity in G5 is more severely decreased than in G4. In patients with severe GHD (G4 + G5), pretreatment HtSDS and BA/CA ratio were both lower than those in G3. Accordingly, severe GHD is highly probable when all peak GH values to provocative stimuli are below 2 mg/L. Related to this, peak GH value is defined as below 3 mg/L after ITT (insulin tolerance test) for the diagnosis of profound adult GHD [12] . It is assumed that the etiology of G5 might be different from that of G2, G3 and G4. Clinical and endocrine data might reveal a spectrum of difference according to the severity of GH deficiency, since HtSDS and IGF-I SD scores in G3 were both lower than those in G2.
After the hGH treatment, the final height and final height SDS in G5 remained the lowest. Nevertheless, the DHtSDS value in G5 was the greatest among the four (G2 to G5) groups. From these data, early treatment starting before significant height deficit develops is desirable in G5 to achieve better final height [13] , although hGH treatment in this group was started earlier than the other groups (G2 to G4).
In conclusion, the percentage of severe short stature with severe GH deficiency (G5) is only 0.6% of IGHD. Growth failure in G5 seems to occur after birth, and the etiology of growth failure might be different from that of other patients with IGHD. Further study is necessary to elucidate the precise incidence of the abnormalities of GH gene or GH related genes in G5. Early diagnosis and hGH treatment are needed to achieve better final height.
